BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

Nestlé Health Science’s premium-priced takeout of peanut allergy company Aimmune is its biggest move yet in biotech, giving it full control of a marketed program in which the nutrition company had already invested heavily. The...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

Riverhead, Ping An lead Lepu’s megaround Lepu Biotechnology Co. Ltd. raised RMB1.3 billion ($185.3 million) in a series B round jointly led by Riverhead Capital and Ping An Capital, with participation by Haitong Innovation Capital Management,...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

FDA’s approval of Aimmune’s peanut allergy therapy continues the momentum of what’s expected to be a big year for approvals in indications with no available treatment options. The agency approved Palforzia Friday to reduce the...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in...
BioCentury | Sep 18, 2019
Company News

FDA panel backs Aimmune’s peanut allergy therapy, wants expanded REMS

Despite concerns over a new surrogate endpoint and increased risk of allergic reactions, the very thing the treatment is designed to diminish, an FDA advisory panel voted 7-2 in favor of the efficacy of Aimmune’s...
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
Items per page:
1 - 10 of 563
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

Nestlé Health Science’s premium-priced takeout of peanut allergy company Aimmune is its biggest move yet in biotech, giving it full control of a marketed program in which the nutrition company had already invested heavily. The...
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

Riverhead, Ping An lead Lepu’s megaround Lepu Biotechnology Co. Ltd. raised RMB1.3 billion ($185.3 million) in a series B round jointly led by Riverhead Capital and Ping An Capital, with participation by Haitong Innovation Capital Management,...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

FDA’s approval of Aimmune’s peanut allergy therapy continues the momentum of what’s expected to be a big year for approvals in indications with no available treatment options. The agency approved Palforzia Friday to reduce the...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in...
BioCentury | Sep 18, 2019
Company News

FDA panel backs Aimmune’s peanut allergy therapy, wants expanded REMS

Despite concerns over a new surrogate endpoint and increased risk of allergic reactions, the very thing the treatment is designed to diminish, an FDA advisory panel voted 7-2 in favor of the efficacy of Aimmune’s...
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
Items per page:
1 - 10 of 563